Reliable and Rapid Testing for COVID-19 with ender MASS

ender diagnostics launches their second CE-certified COVID-19 test, which will enable rapid, and high-volume testing in schools, manufacturing facilities, hospitals, and care homes.

One of the essential elements for the control of COVID-19 is reliable and rapid testing. However, testing capacity is a significant global challenge due to shortages in healthcare services.

Our portfolio company ender diagnostics launches ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus behind the COVID-19 pandemic. With ender MASS, it only takes 30 minutes to diagnose COVID-19. It considerably reduces the workload for medical professionals and laboratories. Moreover, it enables on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations.

«Constant rapid and flexible testing is key in controlling the COVID-19 pandemic, and enabling countries and economies around the world to open up and recover.» comments Tim Pfister, CEO of ender diagnostics «ender diagnostics is well placed to make a significant impact to help avoid partial or large-scale lockdowns around the world. » 

PR_enderMASS_EN

 

HEMEX supports the ender team with clinical, regulatory, and marketing services. HEMEX’s regulatory experts will support the CE-certification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

ARTIDIS Meets Primary Endpoints in First Prospective Study

Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. 

 

ARTIDIS AG CLINICAL STUDY PRESS RELEASE_ULTIMATE_FINAL_fixed_mgmt_Dr Burian alone

 

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/

Rapid COVID-19 Diagnostic Test – launched by ender diagnostics!

Swiss-based start-up ender diagnostics develops rapid molecular tests for the detection of SARS-CoV-2. The first rapid test has just been CE -certified and can now be used in laboratories worldwide.

What makes the ender LAB and subsequent ender MAS test outstanding is not just that the result is obtained within 30 minutes, but also that its accuracy is comparable to the current gold standard. The ender team has extensive experience in developing molecular biological rapid tests. 

PR_CE mark for ender LAB_20200615

 

 

HEMEX supports ender’s team with clinical, regulatory and marketing services. HEMEX’s regulatory experts will support with the CE-certification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

Swiss TPH Receives Grant from BRCCH To Combat COVID-19 with Support of the M4IVD Association

Swiss TPH in Basel submitted one of eleven projects that will receive funding from the Botnar Research Centre for Child Health (BRCCH) and Fondation Botnar. This Fast Track Call for Acute Global Health Challenges (FTC) is a new initiative that supports research in three areas to respond to the global COVID-19 crisis.

Swiss TPH (Tropical and Public Health Insitute) is a world-leading institute in global health focusing on infectious and non-communicable diseases, environment, health systems and interventions.

HEMEX, a founding member of the M4IVD association, is proud to have contributed to this success, together with other M4IVD members University of Basel, ETH Zurich, CSEM (Centre Suisse d’Electronique et de Microtechnique), FHNW (Fachhochschule Nordwestschweiz), BioInitials AG and Effectum Medical AG.

BRCCH_Press Release_May 2020_Successful FTC_CONFIDENTIAL DRAFT

Rapid Testing For Acute COVID-19

Reliable, fast and cost effective, are the attributes of the new COVID-19 testing kits that will be launched shortly by ender diagnostics ag.

The recently incorporated Swiss start-up ender diagnostics can rely on a skilled and experienced team of scientists and entrepreneurs, developing molecular biological rapid tests for infectious diseases. The ender testing kit provides rapid and reliable results for acute COVID–19. Capable of diagnosing multiple samples at once and within just 30 minutes, their first of 3 products “ender LAB”  can diagnose several hundred samples simoultaneously,  and  will thus reduce the time needed to get a reliable diagnosis significantly.

PR_ender LAB_20200506_EN

 

HEMEX supports the ender team with clinical, regulatory and marketing services. HEMEX’s regulatory experts will support with the CE-certifification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

COVID-19 Realtime Tracking App Available in Switzerland and Germany Now

Hand holding mobile with geoHealthApp for COVID-19 tracking

The new GeoHealthApp enables users in Germany and Switzerland to determine their individual infection risk for COVID-19, thus making a pivotal contribution to reduce the spread of SARS-CoV2.

Through a traffic light system on their smartphone display, users receive information about individualized current infection risks. The information results from the frequented locations of the past 14 days as well as personal information related to symptoms. An interactive map shows areas with high infection rates, that can be avoided. The provision of personal data is voluntary and anonymous. No personal data is passed on to any third parties.

After successful launch of the Betaversion some weeks ago, GeoHealthApp today announced the launch of the app that will enable people to protect themselves more quickly and better against pandemic crises, in particular against the current COVID-19 spread.

The app is free of charge in Germany and Switzerland and can be downloaded from the App Store and the Google Play store.

2404_geoHealthApp-Onepager-AJ

 

 

GeoHealthApp received the support from HEMEX, whose regulatory experts helped to register the software as a CE-certified medical device under the European Medical Device Regulation, and also make sure that all data are handled in full compliance with General Data Protection Regulations (GDPR).

Annaida Technologies SA Closes CHF 1M Seed Financing Round

Lausanne, 09 April 2020

Annaida Technologies SA today closed an oversubscribed seed financing round led by HEMEX. Zürcher Kantonalbank, Fongit Seed Invest (FSI), Business Angels Switzerland (BAS), Privilège Ventures, Venture Kick and an angel investor also joined the round to support the start-up developing non-invasive embryo screening technology.

Every year more couples turn to In Vitro Fertilization (IVF) when trying to conceive. The unreliability of IVF multiplies costs as more cycles and tests are required, adding to the emotional and physical burden of such procedures. A crucial aspect of the cycle is the choice of the best embryo for transfer, the one with the highest chance of becoming a healthy baby. Current methods, by examination under a microscope or by taking a biopsy of as much as 15 percent of the embryo’s cells, are too qualitative or too slow and invasive, resulting in successful pregnancies 35 percent of the time on average. Doctors need something better.

To improve the IVF process, a non-invasive yet quantitative embryo screening method is highly sought after. EPFL spin-off Annaida is developing the device to achieve it, harnessing a technology that is delicate enough to use on a human embryo. The startup’s device performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. Like an MRI scanner, shrunk to suit embryos about one-fifth of a millimeter in size the device will allow IVF clinics to perform their analysis on-site and within an hour. Fertility is a growing global market, already worth over CHF 20 billion, with patients already spending over 1 billion on screening embryos for viability. Europe’s clinics perform over 700,000 cycles every year, more than any other continent, making it the ideal place to start. Beyond IVF, Annaida’s device can enable other valuable applications in biochemical research and pharmacology. This is only the beginning.

Annaida Technologies SA was incorporated in June 2019 with a first investment by HEMEX and an angel investor. The funds allowed for substantial advancements to the device and the establishment of essential collaborations for future progress. The goal of the current, milestone-based CHF 1M seed round is to validate the device’s safety and to run preclinical trials to define biomarkers for embryo viability.

“In this round we are adding a diverse set of investors which provide a unique mix of relevant expertise, a valuable network, ability to further support Annaida in the future and the stability needed to fully realize our potential. We are fortunate to have investors that share our vision and see beyond the uncertainties of today’s market” said CEO Gora Conley.

“With this support we are now able to push forward our development towards a technology that will have unparalleled performance, high resolving power, and that is safe for use on something as delicate as a human embryo. Annaida will bring µNMR, and the know-how we are developing, to areas where the current solutions simply don’t offer enough” said CTO Marco Grisi.

ABOUT ZÜRCHER KANTONALBANK
Zürcher Kantonalbank is a leading universal bank in the Zurich economic area with Swiss roots and international reach. It is an independent, incorporated public-law institution of the Canton of Zurich and has received top ratings from the rating agencies Standard & Poor’s, Moody’s and Fitch (AAA/Aaa). With more than 5,000 employees, Zürcher Kantonalbank offers its clients a comprehensive range of products and services. The bank’s core activities include financing businesses, asset and wealth management, trading, capital market transactions, deposits, payment transactions and the card business. Zürcher Kantonalbank provides clients and distribution partners with a comprehensive range of investment and retirement provision products and services.

ABOUT HEMEX
HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/

ABOUT FONGIT SEED INVEST (FSI)
Fongit Seed Invest (FSI) is a Geneva based Seed-Money Fund investing in young technology companies since more than 20 years. It provides smart seed capital and it actively assists entrepreneurs to foster, expand and strengthen their venture by leveraging its strong network of partners and experts. FSI focuses in ventures having disruptive, proprietary and patented enabling technologies and solely invests in fully committed teams capable of delivering rapidly unique and innovative products and technology-based solutions. 

ABOUT PRIVILEGE VENTURES
Privilège Ventures invests mainly in Swiss and European seed level companies – often we are the first professional investor on the cap table. We have more than 20 companies in the combined portfolio of Fund I and II. We believe in deeptech driven by compelling entrepreneurs allowing the creation of value for our investors over time. 

ABOUT BUSINESS ANGELS SWITZERLAND
BAS (Business Angels Switzerland), founded in 1997 and the oldest business angels club in the country, supports startup companies through capital financing. BAS members invest their own time and money and have financed more than 150 startups within the framework of the club with a track record of more than 9 Exits. Alone in 2019 over CHF 2,3m were invested in 17 startups, 1st round or follow on rounds. Members also share expertise, know-how and personal contacts with the companies they invest in. 

ABOUT VENTURE KICK
Venture Kick kicks spin-off projects out of Swiss university labs by providing up to CHF 150,000 in seed-money, a global network to investors and hands-on coaching. Venture Kick is organized as a fully private and philanthropic foundation with the goal of fostering job creation, and social and economic prosperity in Switzerland. Since 2007, Venture Kick has invested CHF 30 million in 700 projects, which today represent 519 companies and more than 7,000 jobs. Startups supported by Venture Kick have raised more than CHF 3.5 billion in investments to date. www.venturekick.ch/portfolio  

For further information please contact:
Annaida Technologies SA
Dr. Gora Conley, CEO
info@annaida.ch
+41 78 631 33 53